ReviewJACC. CardioOncology2025
Cancer-Related Immune Therapies: Bidirectional Implications From Cardiotoxicity to Emerging Cardiovascular Therapeutics: JACC CardioOncology State-of-the-Art Review.
Review in JACC. CardioOncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The New Cardio-Oncology Frontier in Hematologic Cancers: Cardiovascular Toxicities of CAR-T Cells and Bispecific T-Cell Engagers.Journal of clinical medicine · 2026Review
- Functional Heterogeneity of Immune Cell Subpopulations in Atherosclerosis: From Basic Mechanisms to Precision Therapy.Reviews in cardiovascular medicine · 2026Review
- Long-term mortality and acute complications after percutaneous pericardiocentesis in cancer and noncancer patients presenting with severe pericardial effusion.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Impact of CaInternational journal of molecular sciences · 2026Review
- Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune-Metabolic Myocardial Injury with Translational Cardio-Oncology.International journal of molecular sciences · 2026Review
- Cardiac fibroblasts in myocardial injury and heart failure.European heart journal · 2026Review
- Prevalence of obstructive coronary artery disease in asymptomatic cancer patients with elevated troponin levels.Cardio-oncology (London, England) · 2026Article
- Immuno-inflammatory-metabolic interactions in cardiovascular diseases: a review from basic mechanisms to clinical translation.Frontiers in immunology · 2026Review
- The toxicity profile and temporal dynamics of dual PD-1/CTLA-4 immune checkpoint blockade: a real-world pharmacovigilance study using the FAERS database.Frontiers in immunology · 2026Article
- Immune Checkpoint Dysregulation in Autoimmune Disorders: A Narrative Review of Therapeutic Implications.Cureus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-based therapies-including immune checkpoint inhibitors, bispecific T cell engagers, chimeric antigen receptor T cells, and tumor-infiltrating lymphocytes- not only have transformed cancer treatment, but also have introduced significant cardiovascular complications, posing new challenges for cardio-oncology. Growing recognition of cardiovascular immune-related adverse events has spurred research into the immune-cardiovascular interface, particularly dysregulated signaling, T cell overactivation, and cytokine release. This review synthesizes recent insights into the role of immune checkpoints in cardiovascular disease, the mechanisms of immune checkpoint inhibitor- and T cell-induced cardiotoxicity, and the therapeutic potential of immune checkpoint modulation and chimeric antigen receptor T cell therapy in cardiovascular applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.